Ardent Health raises 2026 adjusted EBITDA guidance after strong Q3 results
Ardent Health reported third‑quarter 2026 revenue of $1.62 billion, a 3.1% year‑over‑year increase, and net income of $45 million, or $0.31 per diluted share, compared with a loss a year earlier. Adjusted EBITDA reached $138 million, prompting the company to lift the midpoint of its 2026 adjusted EBITDA outlook to $500‑$535 million. The board also approved an additional $25 million for the share‑repurchase program and announced a definitive agreement to sell its Kansas hospital for roughly 11 times EBITDA.
Why it matters
The higher adjusted EBITDA guidance expands the upside potential for investors, as the company now expects $500‑$535 million versus the prior $485‑$535 million range. The $25 million increase to the buyback program signals confidence in cash generation and may support the share price.
Key facts
- 1Total revenue for Q3 2026 was $1.62 billion, up 3.1% year over year. stocktitan.net
- 2Net income for the quarter was $45 million, or $0.31 per diluted share, versus a loss of $23 million, or $0.17 per diluted share, in Q3 2025. stocktitan.net
- 3Adjusted EBITDA for Q3 2026 was $138 million. stocktitan.net
- 4The company raised the midpoint of its 2026 adjusted EBITDA guidance to $500‑$535 million, up from $485‑$535 million. tradingview.com
- 5The board approved an additional $25 million for the share‑repurchase program. tradingview.com
- 6Ardent Health agreed to divest its Kansas hospital at an implied multiple of 11 times EBITDA, expected to close in Q4 2026 and to improve margins by about 40 basis points. finance.yahoo.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.